Hemochromatosis & Iron-Overload Hypogonadism
HFE iron overload depositing in the pituitary and testes (the reversible miss)
Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Treated with therapeutic phlebotomy (procedure) and chelation
Reference only. Not medical advice.
This is something to take to a clinician. The Atlas can tell you what is known about hemochromatosis & iron-overload hypogonadism in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Hereditary hemochromatosis causes the body to absorb and store excess iron, much of it from HFE gene mutations (around 90 percent of cases are C282Y homozygotes). Iron deposits in the anterior pituitary, and less often the testes, impairing gonadotropin or testosterone output. Hypogonadism is the most common endocrine complication and a frequent cause of low libido and erectile dysfunction in affected men. Critically, in some men iron-depletion therapy can restore sex hormone levels and sexual function, making this a cause clinicians should not overlook.
Rust in the pituitary, and one of the few low-T causes you can drain away.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
How it works
Excess iron is deposited in the anterior pituitary gonadotrophs, blunting LH and FSH secretion and producing a hypogonadotropic (secondary) pattern, the most common mechanism. Less commonly, testicular iron deposition causes a primary hypogonadism. Either way the result is low testosterone. Because iron-driven tissue injury can be partly halted or reversed by removing iron, early treatment can preserve or restore gonadal function.
Why draining iron can beat a testosterone prescription
This is the textbook reversible cause that gets missed because the presenting complaints, fatigue, low libido, joint aches, ED, are generic. The fix is not necessarily lifelong testosterone but therapeutic phlebotomy: reported case series describe testosterone and sexual function returning to normal after iron depletion, especially when treatment starts early.
What it does to fertility
Because much of the defect is pituitary, gonadotropin therapy can be used when fertility is desired, and iron depletion may improve the axis. Reversibility is greatest when iron overload is treated early before fibrotic damage is established.
What has to be monitored
The bloodwork this needs, and the reason it belongs with a clinician rather than a website.
- Transferrin saturation and serum ferritin
- LH, FSH and total testosterone
- Liver function and glucose (associated organ involvement)
- Response of hormones to phlebotomy
What people get wrong
Often saidLow testosterone from hemochromatosis just means lifelong testosterone therapy
ActuallyNot necessarily. Therapeutic phlebotomy can restore sex hormones and sexual function in some men, particularly when iron overload is caught early, which is why the underlying cause must be identified.
Often saidHemochromatosis is only a liver disease
ActuallyIron also targets the pituitary, pancreas, heart and joints; hypogonadism is the most common endocrine consequence and is sometimes the presenting clue.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
At a glance
- Genetics
- ~90% of cases are HFE C282Y homozygotes
- Predominant site
- Pituitary iron deposition (secondary hypogonadism) most common
- Screening labs
- Transferrin saturation >45% and elevated ferritin prompt workup
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Hemochromatosis & Iron-Overload Hypogonadism. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- What can go wrong. We have not written the risk line for this one. Read the safety section below rather than treating its absence as reassurance.
- Where we land. We have not taken a position on this yet.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Kelly et al., Hypogonadism in hemochromatosis: reversal with iron depletion1984
Documented restoration of testosterone and sexual function after iron depletion in affected men
Hypopituitarism in primary haemochromatosis; recovery after iron depletion1995
Reported recovery of pituitary function following iron-removal therapy
AFP / EASL hemochromatosis reviews2021
Define screening thresholds (transferrin saturation >45%, elevated ferritin) and phlebotomy targets